Compare Akamai Technologies, Inc. (AKAM) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Akamai Technologies, Inc. vs Ginkgo Bioworks Holdings Inc — how do they compare? Akamai Technologies, Inc. trades at $123.62 (market cap $16.77B), while Ginkgo Bioworks Holdings Inc trades at $7.34 (market cap $505.73M). The key difference: Akamai Technologies, Inc. is far larger — about 33.2× Ginkgo Bioworks Holdings Inc's market cap, and Akamai Technologies, Inc. is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| AKAM | DNA | |
|---|---|---|
Market Cap | $16.77B | $505.73M |
Sector | Technology | Health |
52-Week High | $161.14 | $16.14 |
52-Week Low | $71.97 | $5.48 |
Enterprise Value | $22.75B | $607.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Akamai Technologies (AKAM) trades at $123.20, up 4.72% with strong quarterly earnings beats and accelerating cloud infrastructure growth. The stock shows mixed technical signals with bearish moving averages but neutral oscillators. Recent Q2 2026 results exceeded expectations with $1.59 EPS versus $1.57 estimate, driven by 39% growth in Cloud Infrastructure Services. However, net income margins have declined from 14.47% in 2022 to 9.51% currently due to increased infrastructure investments.
Akamai presents a compelling growth story in AI and cybersecurity markets with analyst consensus target of $150.11 suggesting 22% upside potential. Key risks include margin pressure from heavy infrastructure spending and competitive threats in cloud services. The balanced analyst rating distribution (47% Buy, 49% Hold) reflects cautious optimism about the company's strategic positioning amid ongoing profitability challenges.
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
